A phase IV study to determine the oral and genital tract concentration of Maraviroc required for ex vivo protection from HIV-1 using Maraviroc 300mg stat
Phase of Trial: Phase IV
Latest Information Update: 25 Mar 2019
At a glance
- Drugs Maraviroc (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- 25 May 2015 Status changed from active, no longer recruiting to completed.
- 08 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
- 07 Nov 2014 Accrual to date is 103% according to United Kingdom Clinical Research Network.